Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from MRTX

Expert Ratings for Mirati Therapeutics

Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings:

Benzinga · May 24, 2022

Analyst Ratings for Mirati Therapeutics

Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings:

Benzinga · May 5, 2022

Mirati Therapeutics: Q1 Earnings Insights

Mirati Therapeutics (NASDAQ:MRTX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Benzinga · May 4, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Earnings Preview For Mirati Therapeutics

Mirati Therapeutics (NASDAQ:MRTX) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Mirati Therapeutics will report an earnings per share (EPS) of $-3.49.

Benzinga · May 3, 2022

Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why

Truist has initiated coverage on Verastem Oncology Inc (NASDAQ:VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside. Analyst Srikripa Devarakonda notes that trading at about 2-times cash, the stock is "undervalued" given its programs in two cancers. Devarakonda adds that the Verastem base case is supported by a…

Benzinga · Mar 9, 2022

Mirati Therapeutics's Return On Capital Employed Overview

Benzinga Pro data, Mirati Therapeutics (NASDAQ:MRTX) reported Q4 sales of $299.00 thousand. Earnings fell to a loss of $199.62 million, resulting in a 149.36% decrease from last quarter.

Benzinga · Mar 2, 2022

Where Mirati Therapeutics Stands With Analysts

Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings:

Benzinga · Mar 1, 2022

Read news from The Economist, FT, and more,
with one subscription

Mirati Therapeutics Posts 41% Objective Response Rate In Pretreated GI Cancer Patients

Mirati Therapeutics Inc (NASDAQ: MRTX) has announced

Benzinga · Jan 21, 2022

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Places

United States

423,139 stories

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.